More Related Content
More from Mihaiela Fazacas (20)
Recently uploaded (20)
Rusu Cristina Rm B Rare Cluj
- 1. DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH MENTAL RETARDATION AND MULTIPLE CONGENITAL ANOMALIES IASI MEDICAL GENETICS CENTERS EXPERIENCE Rusu Cristina (1), Volosciuc M. (1), Braha E. (1), Butnariu L. (1), Panzaru M. (1), Popescu R. (1), Caba L (1), Ivanov Iuliu (2), Gorduza Vlad (2), Covic Mircea (1) (1) Medical Genetics Centre, Sf. Maria Childrens Hospital, Iasi, Romania; (2) Immunology and Genetics Lab, Sf. Spiridon Hospital, Iasi, Romania
- 2. MENTAL RETARDATION DEFINITIONS Mental retardation (MR) = QI < 70; Prevalence: 3%; Mild MR - 7-10 x more frequent than moderate/ severe MR; Evaluation supposes gathering information from specialists (educator, psychologist, physician) + parents; Classification: Mild (IQ 50-70) 85%; Moderate (IQ 35-50) 10%; Severe (IQ 20-35); Profound (IQ <20); 13/07/09 2
- 3. MENTAL RETARDATION DETERMINISM Variable according to MR severity; Mild MR: o Environment 75-90% (social factors !); o Genetic factors 10-25%; Severe MR: o Environment 50%; o Genetic factors 50% (monogenic/ multifactorial disorders/ chromosomal abnormalities). 13/07/09 3
- 4. MODERATE / SEVERE M.R. GENETIC CAUSES CHROMOSOMAL ABNORMALITIES: Numerical: trisomy 21, 13, 18, Klinefelter karyotype; Structural: Deletions/ duplications: 4p-, 5p- karyotype; Microdeleions/ duplications: Sdr Williams, Prader Willi, Angelman FISH; Subtelomeric rearrangements MLPA; MONOGENIC DISORDERS: X-linked mental retardation: Fragile X syndrome DNA test (PCR, Southern blot); Metabolic disorders: Lesch Nyhan, Menkes biochemical test. POLYGENIC CAUSES MITOCHONDRIAL DISORDERS 13/07/09 4
- 5. MATERIAL AND METHOD We have designed, optimized and applied an investigation protocol for mentally retarded individuals; the protocol: Covers most genetic causes of moderate/ severe MR; Adapted to our lab (equipments/ cost of the reagents); We have taken 200 mentally retarded patients examined in Iasi Medical Genetics Center and analyzed the efficiency of the protocol: If De Vries score (proposed for subtelomeric rearrangements identification) could be used broadly for chromosomal abnormalities detection; If the results provided by screening methods (antiFMRP test and MLPA) are concordant with diagnostic tests (long range PCR and FISH); If the methods chosen are reliable;
- 6. PROTOCOL OPTIMIZATION Use selection scores, so that the percent of positive tests will be good enough; Choose the cheapest, less dangerous method that provides good results; Use a sequence of reactions: first screening tests and then diagnostic tests, so that the abnormality will be identified precisely in the end; Reducing the cost by reducing the amount of reagents used;
- 7. CLINICAL PROTOCOL PERSONAL HISTORY (pre/intra/postnatal exclude MR produced by the environment); Extended FAMILY HISTORY pedigree; ANTHROPOMETRIC MEASUREMENTS (Ht, Wt, HC, others); Detailed PHYSICAL EXAMINATION (+ photos); PSYCHOLOGIC EVALUATION; EVALUATION DE VRIES SCORE for case selection; TEST the child with MR anomalies identified test the parents; GENETIC COUNSELLING (before test, followed by written consent of the parents; new session when test results were available); Data recorded in a DATABASE specially designed;
- 8. DE VRIES SCORE (2001): 3/> points necessary Criteria Score Mental retardation family history Compatible with monogenic inheritance 1 Incompatible with monogenic inheritance (including discordant phenotypes) 2 Prenatal onset growth retardation 2 Abnormal postnatal growth (1 point each, maximum 2 points) Microcephaly 1 Short stature 1 Macrocephaly 1 Tall stature 1 2/> facial anomalies (mostly hypertelorism, nasal and auricular defects) 2 Extrafacial anomalies (1 point each, maximum 2 points), especially: Hand anomalies 1 Heart defects 1 Hypospadias +/- criptorchydism 1
- 9. INVESTIGATION PROTOCOL KARYOTYPE ( numerical & structural chromosomal abnormalities); BARR TEST for cases that associate abnormal sexual development; Fragile X screening and diagnosis done for cases with speech delay/ autism (early signs of Fragile X); positive & negative samples included; ANTI-FMRP TEST (immunohistochemical test done on hair root) screening; Long range PCR (identifies premutations and complete mutations) diagnostic; MLPA (2 separate kits P036 and P070) subtelomeric rearrangements (if the results in both kits are abnormal) and polymorphisms (if the result is abnormal in a single kit); FISH microdeletions / confirm subtelomeric rearrangements; DNA stored for subsequent tests (after parental consent);
- 10. RESULTS 53% of patients (106) have been selected for genetic testing; the rest were due to social causes/ perinatal events/ fetopathies etc; 4 patients had specific monogenic disorders and a DNA sample has been taken for further confirmation; 15 patients had a Barr test 3 cases confirmed; 99 patients had a karyotype 43 cases identified; many of them were Down syndrome; 7 patients had a FISH test for microdeletion 1 case confirmed; 55 patients had a MLPA test 4 cases identified; FISH confirmation is in due course; 8 patients had FraX testing all normal; Structural chromosomal abnormalities identified by karyotype have been confirmed by MLPA.
- 11. TEST EFFICIENCY 100% 90% 80% 70% 60% 50% Abnormal Normal 40% 30% 20% 10% 0% Barr Kar FISH MLPA FraX
- 14. 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2 01-001.2 SCNN1D 01-001.0 TNFRSF18 01-247.1 SH3BP5L 02-000.3 ACP1 02-000.3 ACP1 02-241.2 CAPN10 03-000.3 CHL1 03-000.3 CHL1 03-198.8 BDH1 04-000.5 GPI7 04-000.3 ZNF141 04-191.1 FRG1 05-000.3 PDCD6 05-000.3 LOC133957 05-180.6 GNB2L1 06-000.3 IRF4 06-000.3 IRF4 06-170.7 PSMB1 07-000.9 CENTA1 07-000.9 UNC84A 07-158.6 VIPR2 08-000.4 FBXO25 08-000.4 FBXO25 08-144.6 ZC3H3 09-000.9 DMRT1 09-000.4 DOCK8 09-139.8 EHMT1 10-000.5 DIP2C 10-000.2 ZMYND11 10-135.0 PAOX 11-000.2 RIC8A 11-000.2 BET1L 11-133.6 hCAP-D3 12-000.12 SLC6A12 12-000.3 JARID1A 12-132.2 ZNF10 Mapview 13-019.2 PSPC1 Mapview 13-019.2 PSPC1 13-112.8 F7 14-019.9 CCNB1IP1 14-019.9 PARP2 po36-88.D04_08121819RL^CEQsCSV.csv 14-105.0 MTA1 15-021.5 NDN 15-021.4 MKRN3 15-099.3 ALDH1A3 P070.88.G01_09032408H9^CEQsCSV.csv 16-000.4 DECR2 16-000.04 POLR3K 16-088.6 GAS8 17-000.1 RPH3AL 17-000.1 RPH3AL 17-078.4 TBCD 18-000.2 THOC1 18-000.2 USP14 18-075.9 C18orf22 19-000.2 PPAP2C 19-000.5 CDC34 19-063.8 CHMP2A 20-000.2 ZCCHC3 20-000.3 SOX12 20-062.2 OPRL1 21-014.7 STCH 21-014.5 RBM11 21-046.9 HRMT1L1 DUPLICATION 9p 22-016.0 IL17R 22-016.6 BID 22-049.6 RABL2B X-000.5 SHOX X/Y-000.5 SHOX (PAR region) X/Y-154.8 SYBL1 (PAR region)
- 16. Ratio 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 01-001.0 TNFRSF18 02-000.3 ACP1 03-000.3 CHL1 04-000.3 ZNF141 5-000.3 LOC133957 06-000.3 IRF4 07-000.9 UNC84A 08-000.4 FBXO25 09-000.4 DOCK8 10-000.2 ZMYND11 11-000.2 BET1L 12-000.3 JARID1A 13-019.2 PSPC1 14-019.9 PARP2 15-021.5 NDN P070.111.H01_09032408HA^CEQsCSV.csv 16-000.4 DECR2 17-000.1 RPH3AL 18-000.2 THOC1 19-000.2 PPAP2C 20-000.2 ZCCHC3 21-014.7 STCH 22-016.0 IL17R dup(21)(q22.3;q11.2) X-000.5 SHOX
- 17. CONCLUSIONS De Vries score - useful for case selection (both chromosomal abnormalities and subtelomeric rearrangements); MLPA - reliable, fast and unexpensive method that can be used as a screening method for subtelomeric rearrangements; MLPA may be used as a complementary method to identify marker chromosomes/ complex chromosomal abnormalities; The protocol could be further optimized by extending MLPA for other applications; Cases with normal results/ polymorphisms - reevaluated in order to get a final diagnosis; Cases identified - followed in order to prevent complications; clinical description of subtelomeric rearrangements is an ongoing process.
- 18. 13/07/09 18